The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.
 
Efstathios Kastritis
Honoraria - Amgen; Genesis Pharma; Janssen Oncology; Pfizer; Prothena; Takeda
Consulting or Advisory Role - Amgen; Genesis Pharma; Janssen Oncology; Pfizer; Prothena; Takeda
Research Funding - Amgen (Inst); Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Genesis Pharma; Janssen Oncology; Pfizer; Takeda
 
Vaishali Sanchorawala
Consulting or Advisory Role - Abbvie; Caelum Biosciences; Janssen Research & Development; Proclara
Research Funding - Celgene (Inst); Janssen (Inst); Oncopeptides (Inst); Prothena (Inst); Takeda (Inst)
 
Giampaolo Merlini
No Relationships to Disclose